Advancements in Lab Automation and Therapeutic Development

7min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Exploring the impact of liquid handle automation, AI in protein structure work, and the benefits of automating laboratory processes in biotech. Highlighting the safety advantages of antibody development, challenges in therapeutic development, and the importance of data-driven problem-solving in the biotech industry.

Antibodies are a type of protein molecule produced by the immune system. They recognize and attach to other molecules with remarkable precision. Typically antibodies target foreign objects, like viruses, to mark them for destruction. However, they can also be engineered to treat diseases like cancer, and they are one of the fastest growing classes of drugs.

Recently, AI-driven antibody engineering has taken off, and BigHat Bio is one of the leaders of this revolution.

Eddie Abrams is the Chief Information Officer at BigHat. He joins the show to talk about protein engineering, what’s different about software development in biotech, how the engineering team is organized at BigHat, and more.

Sean’s been an academic, startup founder, and Googler. He has published works covering a wide range of topics from information visualization to quantum computing. Currently, Sean is Head of Marketing and Developer Relations at Skyflow and host of the podcast Partially Redacted, a podcast about privacy and security engineering. You can connect with Sean on Twitter @seanfalconer .